Antifragile Control Systems: The Case of an Anti-Symmetric Network Model of the Tumor-Immune-Drug Interactions
Open Access
- 29 September 2022
- Vol. 14 (10), 2034
- https://doi.org/10.3390/sym14102034
Abstract
A therapy’s outcome is determined by a tumor’s response to treatment which, in turn, depends on multiple factors such as the severity of the disease and the strength of the patient’s immune response. Gold standard cancer therapies are in most cases fragile when sought to break the ties to either tumor kill ratio or patient toxicity. Lately, research has shown that cancer therapy can be at its most robust when handling adaptive drug resistance and immune escape patterns developed by evolving tumors. This is due to the stochastic and volatile nature of the interactions, at the tumor environment level, tissue vasculature, and immune landscape, induced by drugs. Herein, we explore the path toward antifragile therapy control, that generates treatment schemes that are not fragile but go beyond robustness. More precisely, we describe the first instantiation of a control-theoretic method to make therapy schemes cope with the systemic variability in the tumor-immune-drug interactions and gain more tumor kills with less patient toxicity. Considering the anti-symmetric interactions within a model of the tumor-immune-drug network, we introduce the antifragile control framework that demonstrates promising results in simulation. We evaluate our control strategy against state-of-the-art therapy schemes in various experiments and discuss the insights we gained on the potential that antifragile control could have in treatment design in clinical settings.Keywords
This publication has 43 references indexed in Scilit:
- Current Advances in Mathematical Modeling of Anti-Cancer Drug Penetration into Tumor TissuesFrontiers in Oncology, 2013
- "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerNeuro-Oncology, 2011
- Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer ModelingScience Translational Medicine, 2011
- Fluctuations induced extinction and stochastic resonance effect in a model of tumor growth with periodic treatmentPhysics Letters A, 2011
- Resiliency and Vulnerability in the HER2-HER3 Tumorigenic DriverScience Translational Medicine, 2010
- The Hill equation: a review of its capabilities in pharmacological modellingFundamental & Clinical Pharmacology, 2008
- The dynamics of an optimally controlled tumor model: A case studyMathematical and Computer Modelling, 2003
- Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysisBulletin of Mathematical Biology, 1994
- Variable structure control of nonlinear multivariable systems: a tutorialProceedings of the IEEE, 1988
- Variable structure systems with sliding modesIEEE Transactions on Automatic Control, 1977